Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study

(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry....

Descripción completa

Detalles Bibliográficos
Autores principales: Chaparro, María, Garre, Ana, Núñez Ortiz, Andrea, Diz-Lois Palomares, María Teresa, Rodríguez, Cristina, Riestra, Sabino, Vela, Milagros, Benítez, José Manuel, Fernández Salgado, Estela, Sánchez Rodríguez, Eugenia, Hernández, Vicent, Ferreiro-Iglesias, Rocío, Ponferrada Díaz, Ángel, Barrio, Jesús, Huguet, José María, Sicilia, Beatriz, Martín-Arranz, María Dolores, Calvet, Xavier, Ginard, Daniel, Alonso-Abreu, Inmaculada, Fernández-Salazar, Luis, Varela Trastoy, Pilar, Rivero, Montserrat, Vera-Mendoza, Isabel, Vega, Pablo, Navarro, Pablo, Sierra, Mónica, Cabriada, José Luis, Aguas, Mariam, Vicente, Raquel, Navarro-Llavat, Mercè, Echarri, Ana, Gomollón, Fernando, Guerra del Río, Elena, Piñero, Concepción, Casanova, María José, Spicakova, Katerina, Ortiz de Zarate, Jone, Torrella Cortés, Emilio, Gutiérrez, Ana, Alonso-Galán, Horacio, Hernández-Martínez, Álvaro, Marrero, José Miguel, Lorente Poyatos, Rufo, Calafat, Margalida, Martí Romero, Lidia, Robledo, Pilar, Bosch, Orencio, Jiménez, Nuria, Esteve Comas, María, Duque, José María, Fuentes Coronel, Ana María, Josefa Sampedro, Manuela, Sesé Abizanda, Eva, Herreros Martínez, Belén, Pozzati, Liliana, Fernández Rosáenz, Hipólito, Crespo Suarez, Belén, López Serrano, Pilar, Lucendo, Alfredo J., Muñoz Vicente, Margarita, Bermejo, Fernando, Ramírez Palanca, José Joaquín, Menacho, Margarita, Carmona, Amalia, Camargo, Raquel, Torra Alsina, Sandra, Maroto, Nuria, Nerín de la Puerta, Juan, Castro, Elena, Marín-Jiménez, Ignacio, Botella, Belén, Sapiña, Amparo, Cruz, Noelia, Forcelledo, José Luis F., Bouhmidi, Abdel, Castaño-Milla, Carlos, Opio, Verónica, Nicolás, Isabel, Kutz, Marcos, Abraldes Bechiarelli, Alfredo, Gordillo, Jordi, Ber, Yolanda, Torres Domínguez, Yolanda, Novella Durán, María Teresa, Rodríguez Mondéjar, Silvia, Martínez-Cerezo, Francisco J., Kolle, Lilyan, Sabat, Miriam, Ledezma, Cesar, Iyo, Eduardo, Roncero, Óscar, Irisarri, Rebeca, Lluis, Laia, Blázquez Gómez, Isabel, Zapata, Eva María, José Alcalá, María, Martínez Pascual, Cristina, Montealegre, María, Mata, Laura, Monrobel, Ana, Hernández Camba, Alejandro, Hernández, Luis, Tejada, María, Mir, Alberto, Galve, María Luisa, Soler, Marta, Hervías, Daniel, Gómez-Valero, José Antonio, Barreiro-de Acosta, Manuel, Rodríguez-Artalejo, Fernando, García-Esquinas, Esther, Gisbert, Javier P., GETECCU, on behalf of the EpidemIBD study group of
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8268420/
https://www.ncbi.nlm.nih.gov/pubmed/34209680
http://dx.doi.org/10.3390/jcm10132885
Descripción
Sumario:(1) Aims: To assess the incidence of inflammatory bowel disease (IBD) in Spain, to describe the main epidemiological and clinical characteristics at diagnosis and the evolution of the disease, and to explore the use of drug treatments. (2) Methods: Prospective, population-based nationwide registry. Adult patients diagnosed with IBD—Crohn’s disease (CD), ulcerative colitis (UC) or IBD unclassified (IBD-U)—during 2017 in Spain were included and were followed-up for 1 year. (3) Results: We identified 3611 incident cases of IBD diagnosed during 2017 in 108 hospitals covering over 22 million inhabitants. The overall incidence (cases/100,000 person-years) was 16 for IBD, 7.5 for CD, 8 for UC, and 0.5 for IBD-U; 53% of patients were male and median age was 43 years (interquartile range = 31–56 years). During a median 12-month follow-up, 34% of patients were treated with systemic steroids, 25% with immunomodulators, 15% with biologics and 5.6% underwent surgery. The percentage of patients under these treatments was significantly higher in CD than UC and IBD-U. Use of systemic steroids and biologics was significantly higher in hospitals with high resources. In total, 28% of patients were hospitalized (35% CD and 22% UC patients, p < 0.01). (4) Conclusion: The incidence of IBD in Spain is rather high and similar to that reported in Northern Europe. IBD patients require substantial therapeutic resources, which are greater in CD and in hospitals with high resources, and much higher than previously reported. One third of patients are hospitalized in the first year after diagnosis and a relevant proportion undergo surgery.

Ejemplares similares